Clinical analysis platform uMotif has raised £20 million from a New York funding agency.

The London firm’s patient-first software program platform is accessible on any machine and designed to service pharmaceutical, BioTech, MedTech and contract analysis organisation purchasers together with AstraZeneca.

Deployed in additional than 30 nations globally, it claims to ship excessive charges of information seize, affected person retention, information high quality and supply velocity – in the end serving to obtain sooner, higher trials. 

The funding comes from a fund managed by Athyrium Capital Management, which relies in New York. Existing buyers AlbionVC and DNV, which led a Series A funding spherical in 2020, additionally joined. 

It will assist additional worldwide enlargement and continued improvement of patent-protected options for ache, scientific final result and symptom monitoring.  

Having entered the US in 2021, and with assist of a US-based healthcare investor, uMotif’s North American crew will considerably develop – together with in gross sales, advertising and repair supply.  

“We are delighted to welcome Athyrium to assist our journey to be probably the most patient-centric platform for analysis,” stated Steve Rosenberg, CEO. 

“I actually imagine that scientific analysis should put sufferers first, delivering extra participating analysis research.  With this funding from Athyrium I’m excited to develop our world capabilities to higher serve our sponsors, companions and – most significantly – the sufferers we assist participate in analysis.”

‘Launching my first business at 50 has been the best thing I ever did’

Mark Kavulich, associate at Athyrium stated: “Over latest years we have now seen how the worldwide eClinical market is considerably rising and rapidly altering.  uMotif’s strategy to participating sufferers in analysis is actually differentiated, patent-protected and is constructed on know-how able to scale.

“We’re excited to be becoming a member of the uMotif journey and supporting important scale up within the coming years.”


Source link

#Clinical #analysis #platform #uMotif #raises #20m #funding

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *